Orchard Therapeutics Completed The Rolling Submission Of Its Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For Otl-200.
Portfolio Pulse from Benzinga Newsdesk
Orchard Therapeutics has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for OTL-200.
August 04, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Orchard Therapeutics' completion of the rolling submission of its BLA to the FDA for OTL-200 could potentially lead to a positive impact on its stock.
The completion of the rolling submission of a BLA to the FDA is a significant step towards the approval of a new drug. If OTL-200 is approved, it could potentially lead to increased revenues for Orchard Therapeutics, which would likely have a positive impact on its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100